7 active not recruiting, 5 completed, 2 recruiting, 1 withdrawn. 9 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 7, Completed 2 |
| Phase 1 | 6 | Completed 3, Recruiting 2, Withdrawn 1 |
Follow Recurrent Ependymoma: new trials by email Literature Review of Recurrent Ependymoma trials Research Report on Recurrent Ependymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA), Group A Standard-of-Care Backbone Therapy, Group B Salvage Backbone Therapy - Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS | Phase 1 | Recruiting | Children's National Research Institute | 12 | 2024-09-20 | 2026-10-13 |
| Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies Nivolumab, Methotrexate, 5-Azacytidine - Recurrent Ependymoma, Recurrent Medulloblastoma | Phase 1 | Withdrawn | Jeffrey Treiber | 2024-07-15 | 2026-01-08 | |
| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Irinotecan, Temozolomide, Bevacizumab - Recurrent Medulloblastoma, Recurrent Ependymoma | Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 62 | 2022-04-04 | 2026-07-28 |
| ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS) - Diffuse Midline Glioma (DMG), Glioblastoma | Phase 1 | Recruiting | Sabine Mueller, MD, PhD | 208 | 2021-08-23 | 2026-06-11 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma 5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3 - Recurrent Ependymoma | Phase 1 | Completed | The University of Texas Health Science Center, Houston | 3 | 2019-02-08 | 2025-04-08 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors Laboratory Biomarker Analysis, Natural Killer Cell Therapy - Recurrent Childhood Medulloblastoma, Recurrent Ependymoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 12 | 2015-03-17 | 2020-09-02 |
| A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors AdV-tk, valacyclovir, Radiation - Malignant Glioma, Recurrent Ependymoma | Phase 1 | Completed | Candel Therapeutics, Inc. | 8 | 2010-10-01 | 2023-08-25 |
Ependymoma (15) · Medulloblastoma (12) · Glioma (9) · Rhabdoid Tumor (9) · Hepatoblastoma (8) · Histiocytosis, Langerhans-Cell (8) · Lymphoma, Non-Hodgkin (8) · Neuroblastoma (8) · Neuroectodermal Tumors, Primitive, Peripheral (8) · Osteosarcoma (8) · Rhabdomyosarcoma (8) · Sarcoma (8) · Wilms Tumor (8) · Central Nervous System Neoplasms (7) · Sarcoma, Ewing (6)
Neoplasms (15) · Neoplasms by Histologic Type (15) · Neoplasms, Germ Cell and Embryonal (15) · Neoplasms, Glandular and Epithelial (15) · Neoplasms, Nerve Tissue (15) · Neoplasms, Neuroepithelial (15) · Neuroectodermal Tumors (15) · Neoplasms by Site (11) · Neuroectodermal Tumors, Primitive (11) · Neoplasms, Complex and Mixed (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genetic Diseases, Inborn (8) · Hemic and Lymphatic Diseases (8)
Magnetic Resonance Spectroscopy (6) · Phantoms, Imaging (5) · X-Rays (5) · Nuclear Medicine Department, Hospital (4) · Specimen Handling (4) · Biopsy (3) · Azacitidine (2) · LY3023414 (2) · Radiation (2) · Radiotherapy (2) · ensartinib (2) · ivosidenib (2) · larotrectinib (2) · selpercatinib (2) · tazemetostat (2)
National Cancer Institute (NCI) (8) · Candel Therapeutics, Inc. (1) · Children's National Research Institute (1) · Jeffrey Treiber (1) · M.D. Anderson Cancer Center (1) · Pediatric Brain Tumor Consortium (1) · Sabine Mueller, MD, PhD (1) · The University of Texas Health Science Center, Houston (1)
United States (14) · Puerto Rico (8) · Australia (4) · Canada (2) · Netherlands (1) · Switzerland (1)
Andrea T Franson (1) · Brian Rood, MD (1) · Christine A Pratilas (1) · David I Sandberg, MD (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · Jeffrey M. Treiber, MD (1) · Katherine A Janeway (1) · Matthias Karajannis, MD, MS (1) · Meredith S Irwin (1) · Sabine Mueller, MD, PhD (1) · Soumen Khatua (1) · Susan N Chi (1) · Theodore W Laetsch (1)
PMID 30883662, PMID 31401903, PMID 33591402, PMID 34171339, PMID 34486544, PMID 35157764, PMID 35353553, PMID 41166674, PMID 41256696, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (8), P30CA016672 (1), R01CA266596 (1), UM1CA081457 (1)